Pliant Therapeutics Stock Piotroski F Score

PLRX Stock  USD 13.53  0.19  1.42%   
This module uses fundamental data of Pliant Therapeutics to approximate its Piotroski F score. Pliant Therapeutics F Score is determined by combining nine binary scores representing 3 distinct fundamental categories of Pliant Therapeutics. These three categories are profitability, efficiency, and funding. Some research analysts and sophisticated value traders use Piotroski F Score to find opportunities outside of the conventional market and financial statement analysis.They believe that some of the new information about Pliant Therapeutics financial position does not get reflected in the current market share price suggesting a possibility of arbitrage. Check out Pliant Therapeutics Altman Z Score, Pliant Therapeutics Correlation, Pliant Therapeutics Valuation, as well as analyze Pliant Therapeutics Alpha and Beta and Pliant Therapeutics Hype Analysis.
For more information on how to buy Pliant Stock please use our How to Invest in Pliant Therapeutics guide.
  
At this time, Pliant Therapeutics' Short Term Debt is fairly stable compared to the past year. Long Term Debt is likely to rise to about 11 M in 2024, whereas Short and Long Term Debt Total is likely to drop slightly above 6.5 M in 2024. At this time, Pliant Therapeutics' Capex To Revenue is fairly stable compared to the past year. Tangible Book Value Per Share is likely to rise to 8.47 in 2024, whereas Free Cash Flow Yield is likely to drop (0.12) in 2024.
At this time, it appears that Pliant Therapeutics' Piotroski F Score is Unavailable. Although some professional money managers and academia have recently criticized Piotroski F-Score model, we still consider it an effective method of predicting the state of the financial strength of any organization that is not predisposed to accounting gimmicks and manipulations. Using this score on the criteria to originate an efficient long-term portfolio can help investors filter out the purely speculative stocks or equities playing fundamental games by manipulating their earnings..
2.0
Piotroski F Score - Unavailable
Current Return On Assets

Negative

Focus
Change in Return on Assets

Decreased

Focus
Cash Flow Return on Assets

Negative

Focus
Current Quality of Earnings (accrual)

Improving

Focus
Asset Turnover Growth

Decrease

Focus
Current Ratio Change

Decrease

Focus
Long Term Debt Over Assets Change

Higher Leverage

Focus
Change In Outstending Shares

Decrease

Focus
Change in Gross Margin

No Change

Focus

Pliant Therapeutics Piotroski F Score Drivers

The critical factor to consider when applying the Piotroski F Score to Pliant Therapeutics is to make sure Pliant is not a subject of accounting manipulations and runs a healthy internal audit department. So, if Pliant Therapeutics' auditors report directly to the board (not management), the managers will be reluctant to manipulate simply due to the fear of punishment. On the other hand, the auditors will be free to investigate the ledgers properly because they know that the board has their back. Below are the main accounts that are used in the Piotroski F Score model. By analyzing the historical trends of the mains drivers, investors can determine if Pliant Therapeutics' financial numbers are properly reported.
Current ValueLast YearChange From Last Year 10 Year Trend
Asset Turnover0.00290.0031
Notably Down
Slightly volatile
Gross Profit Margin0.480.56
Fairly Down
Slightly volatile
Total Current Liabilities15.3 M28.5 M
Way Down
Slightly volatile
Non Current Liabilities Total9.6 M10.1 M
Notably Down
Slightly volatile
Total Assets537.8 M512.2 M
Sufficiently Up
Slightly volatile
Total Current Assets530.8 M505.5 M
Sufficiently Up
Slightly volatile

Pliant Therapeutics F Score Driver Matrix

One of the toughest challenges investors face today is learning how to quickly synthesize historical financial statements and information provided by the company, SEC reporting, and various external parties in order to project the various growth rates. Understanding the correlation between Pliant Therapeutics' different financial indicators related to revenue, expenses, operating profit, and net earnings helps investors identify and prioritize their investing strategies towards Pliant Therapeutics in a much-optimized way.

About Pliant Therapeutics Piotroski F Score

F-Score is one of many stock grading techniques developed by Joseph Piotroski, a professor of accounting at the Stanford University Graduate School of Business. It was published in 2002 under the paper titled Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers. Piotroski F Score is based on binary analysis strategy in which stocks are given one point for passing 9 very simple fundamental tests, and zero point otherwise. According to Mr. Piotroski's analysis, his F-Score binary model can help to predict the performance of low price-to-book stocks.

Book Value Per Share

8.47

At this time, Pliant Therapeutics' Book Value Per Share is fairly stable compared to the past year.

Pliant Therapeutics Current Valuation Drivers

We derive many important indicators used in calculating different scores of Pliant Therapeutics from analyzing Pliant Therapeutics' financial statements. These drivers represent accounts that assess Pliant Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Pliant Therapeutics' important valuation drivers and their relationship over time.
201920202021202220232024 (projected)
Market Cap757.2M807.8M483.9M812.2M1.1B1.1B
Enterprise Value671.9M757.2M439.5M794.3M1.0B1.1B

Pliant Therapeutics ESG Sustainability

Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Pliant Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Pliant Therapeutics' managers, analysts, and investors.
Environmental
Governance
Social

About Pliant Therapeutics Fundamental Analysis

The Macroaxis Fundamental Analysis modules help investors analyze Pliant Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Pliant Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Pliant Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Pliant Stock Analysis

When running Pliant Therapeutics' price analysis, check to measure Pliant Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pliant Therapeutics is operating at the current time. Most of Pliant Therapeutics' value examination focuses on studying past and present price action to predict the probability of Pliant Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pliant Therapeutics' price. Additionally, you may evaluate how the addition of Pliant Therapeutics to your portfolios can decrease your overall portfolio volatility.